title: Use of sorafenib in a corticotropin-secreting pancreatic neuroendocrine carcinoma.
authors.affiliation: Regional Centre for Endocrinology and Diabetes, Royal Victoria Hospital, Belfast, United Kingdom qublbc8@hotmail.com Northern Ireland Cancer Centre, Belfast City Hospital, Belfast, United Kingdom Regional Centre for Endocrinology and Diabetes, Royal Victoria Hospital, Belfast, United Kingdom.
authors.forename: Una
authors.initials: U
authors.lastname: Graham
authors.forename: Martin
authors.initials: M
authors.lastname: Eatock
authors.forename: Brew
authors.initials: B
authors.lastname: Atkinson
mesh_terms: D000324:Adrenocorticotropic Hormone / Q000037:antagonists & inhibitors* / Q000378:metabolism; D000970:Antineoplastic Agents / Q000627:therapeutic use; D018278:Carcinoma, Neuroendocrine / Q000188:drug therapy* / Q000378:metabolism; D006801:Humans; D008297:Male; D008875:Middle Aged; D009536:Niacinamide / Q000031:analogs & derivatives* / Q000627:therapeutic use; D010190:Pancreatic Neoplasms / Q000188:drug therapy* / Q000378:metabolism; D010671:Phenylurea Compounds / Q000627:therapeutic use*; D000077157:Sorafenib; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents; D010671:Phenylurea Compounds; D009536:Niacinamide; D000324:Adrenocorticotropic Hormone; D000077157:Sorafenib